The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
A Review of Circulating Tumour Cell Enrichment Technologies
Open accessAbstract
Circulating tumour cells (CTCs) are the precursor cells for the formation of metastatic disease. With a simple blood draw, liquid biopsies enable the non-invasive sampling of CTCs from the blood, which have the potential to provide important insights into cancer detection and monitoring. Since gaining FDA approval in 2004, the CellSearch system has been used to determine the prognosis of patients with metastatic breast, prostate and colorectal cancers. This utilises the cell surface marker Epithelial Cell Adhesion Molecule (EpCAM), to enrich CTCs, and many other technologies have adopted this approach. More recently, the role of mesenchymal-like CTCs in metastasis formation has come to light. It has been suggested that these cells are more aggressive metastatic precursors than their epithelial counterparts; however, mesenchymal CTCs remain undetected by EpCAM-based enrichment methods. This has prompted the development of a variety of ‘label free’ enrichment technologies, which exploit the unique physical properties of CTCs (such as size and deformability) compared to other blood components. Here, we review a wide range of both immunocapture and label free CTC enrichment technologies, summarising the most significant advantages and disadvantages of each. We also highlight the important characteristics that technologies should possess for routine clinical use, since future developments could have important clinical implications, with the potential to direct personalised therapies for patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
Abal, M., Andreu, J., & Barasoain, I. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481967 · Cited by 383
Analyzing Circulating Tumor Cells One at a Time
Ortiz, V., & Yu, M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.05.004 · Cited by 48
Yap, Y.-S., Leong, M. C., Chua, Y. W., Loh, K. W. J., Lee, G. E., Lim, E. H., Dent, R., Ng, R. C. H., Lim, J. H.-C., Singh, G., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0221305 · Cited by 23 · cited 6×
“The ClearCell FX1 platform (Biolidics, Singapore) is a spiral microfluidic device which uses Dean Flow Fractionation (DFF) principles (dean forces and lift forces) to focus and retain larger CTCs at the inner side of the spiral channel whilst the remaining blood components flow through the chip via the outer side of t…”
BackgroundMethodInfluential
Cited by
Liquid biopsy in cancer: current status, challenges and future prospects
Ma, L., Guo, H., Zhao, Y., Liu, Z., Wang, C., Bu, J., Sun, T., & Wei, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02021-w · Cited by 712
Circulating tumor cell isolation for cancer diagnosis and prognosis
Deng, Z., Wu, S., Wang, Y., & Shi, D. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104237 · Cited by 284
Zhou, H., Zhu, L., Song, J., Wang, G., Li, P., Li, W., Luo, P., Sun, X., Wu, J., Liu, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01556-2 · Cited by 261
Network approach in liquidomics landscape
Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02743-9 · Cited by 37
Metadata
- Authors
- Rushton, A. J., Nteliopoulos, G., Shaw, J. A., & Coombes, R. C.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-02-26
- Volume
- 13
- Issue
- 5
- Pages
- 970
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3135446690
- Cited by
- 197
- References
- 6
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review of Circulating Tumour Cell Enrichment Technologies. https://app.cochat.ai/papers/10.3390/cancers13050970
- The paper
- Rushton, A. J., Nteliopoulos, G., Shaw, J. A., & Coombes, R. C. (2021). A Review of Circulating Tumour Cell Enrichment Technologies. Cancers. https://doi.org/10.3390/cancers13050970
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.